Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinical Trial Not Allowed)
ID: 352347Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is soliciting applications for a limited competition cooperative agreement under the funding opportunity titled "Collaborative Study on the Genetics of Alcoholism (COGA)." This initiative aims to advance the understanding of genetic variants that influence susceptibility to alcohol use disorder (AUD) by leveraging existing datasets from current COGA investigators. The research is critical for identifying therapeutic targets and developing preventive strategies related to AUD, focusing on the integration of genetic, behavioral, and environmental factors. The total funding available for this program is $6.5 million, with applications due by April 26, 2024. Interested applicants can find more information and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is soliciting applications for a limited competition cooperative agreement under the funding opportunity titled "Collaborative Study on the Genetics of Alcoholism (COGA)." This initiative aims to explore the genetic variants affecting susceptibility to alcohol use disorder (AUD) to better understand its biological, behavioral, and environmental factors. With a budget of $6.5 million, the program invites proposals from existing COGA investigators to leverage extensive existing datasets involving thousands of participants. The research focuses on complex factors influencing AUD and aims to identify therapeutic targets and develop preventive strategies based on innovative data analysis approaches. Key activities include genetic data analysis, integration of multi-generational datasets, and public sharing of findings through NIH-designated repositories. The application process includes strict guidelines, eligibility requirements, and deadlines, with an emphasis on compliance and collaboration among diverse research teams. The goals of this research initiative are vital for advancing the understanding of AUD and informing public health strategies.
    Similar Opportunities
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alcohol Treatment, Pharmacotherapy, and Recovery Research grant, specifically under the R01 Clinical Trial Required mechanism. This funding opportunity aims to advance research on Alcohol Use Disorder (AUD) by focusing on various aspects such as medication development, behavioral therapies, recovery mechanisms, and innovative treatment technologies. The NIH emphasizes the importance of addressing AUD, particularly for underserved populations, and seeks projects that translate neuroscience research into practical applications. Interested applicants can apply for a grant with an award ceiling of $500,000, with the application process opening on January 5, 2025, and submissions due by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PA-25-163.html.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)." This initiative aims to advance the discovery and development of innovative drug and device therapies targeting mental disorders and alcohol use disorder (AUD) through collaborative efforts among academia, biotechnology, and pharmaceutical sectors. The program emphasizes multidisciplinary approaches and partnerships to facilitate early-phase human trials, develop pharmacologic and neuromodulatory tools, and validate experimental therapeutic studies. Eligible applicants include a wide range of organizations, such as educational institutions and nonprofits, with no cap on application budgets, although realistic estimates are expected. The total project period cannot exceed five years, and applications must adhere to NIH guidelines. Interested parties can find more information and submit inquiries via email to OERWebmaster03@od.nih.gov, with the application deadline set for February 24, 2025.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)" aimed at advancing research in the treatment and recovery from alcohol use disorder (AUD). This grant supports clinical trials focusing on various aspects of AUD, including medication development, behavioral therapies, and innovative treatment technologies, particularly for populations facing health disparities. The funding is crucial for enhancing the understanding and efficacy of AUD treatments, ultimately contributing to improved public health outcomes. Eligible applicants can receive up to $500,000 in direct costs over a maximum project period of five years, with key submission deadlines on October 5, 2023, and February 5, 2024. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-250.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Alcohol Health Services Research (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a funding opportunity titled "Alcohol Health Services Research (R34 Clinical Trial Optional)" (PAR-23-252). This initiative aims to address the treatment gap for individuals with Alcohol Use Disorder (AUD) by focusing on improving access to treatment, reducing stigma, examining cost structures, and implementing evidence-based approaches, particularly for health disparity populations. The total project budget is capped at $450,000 over a three-year period, and eligible applicants include higher education institutions, nonprofits, and government agencies, with a specific emphasis on those serving underrepresented communities. Interested parties should submit their applications electronically by October 16, 2023, with funding available until September 8, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Alcohol Health Services Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a funding opportunity titled "Alcohol Health Services Research (R01 Clinical Trial Optional)" aimed at addressing the treatment gap for individuals with Alcohol Use Disorder (AUD). This initiative focuses on five key areas: increasing access to treatment, enhancing the appeal of treatment options, analyzing cost structures and insurance systems, studying the dissemination of evidence-based practices, and reducing health disparities among affected populations. The program encourages innovative research designs and participation from diverse organizations, with a maximum budget of $500,000 available for direct costs over a five-year project period. Interested applicants can submit proposals starting January 5, 2025, and should direct inquiries to grantsinfo@nih.gov for further information.
    Alcohol Health Services Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for the Alcohol Health Services Research (R01 Clinical Trial Optional) grant. This initiative aims to address the treatment gap for individuals with Alcohol Use Disorder (AUD) by focusing on five key areas: increasing access to treatment, enhancing the appeal of treatment, examining cost structures and insurance systems, studying the dissemination and implementation of evidence-based approaches, and reducing health disparities among affected populations. The grant allows for a maximum budget of $500,000 and a project period of up to five years, with applications due by September 7, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on Alcohol Treatment, Pharmacotherapy, and Recovery under the R34 Clinical Trial required mechanism. This initiative aims to address the treatment gap for individuals with alcohol use disorder (AUD) by focusing on five key areas: increasing access to treatment, enhancing treatment appeal, examining cost structures, studying dissemination of evidence-based approaches, and reducing health disparities. With AUD being a significant global health issue, this funding seeks to improve treatment methods and recovery pathways, particularly for underserved populations. Applications will be accepted starting January 16, 2025, with a maximum project period of three years and direct costs capped at $450,000. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-193.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.